

Clinical Trial Protocol

Iranian Registry of Clinical Trials

17 Sep 2026

The effects of Amitriptylline and Tamsulocin on the urinary symptoms of patients with ureteral stent, a randomized clinical trial.

Protocol summary

Summary

The purpose of this study is to investigate the effects of Amitriptylline and Tamsulocin on the urinary symptoms due to ureteral stent. In this randomized clinical trial study, 210 patients who have urinary obstruction of upper urinary tract who are candidate for unilateral ureteral stent will be randomized into one of the following intervention groups. The patients will receive Tamsulocin, 0.4 mg daily, Amitriptylline, 25 mg/daily, or both Amitriptylline, 25 mg daily and Tamsulocin, 0.4 mg daily for three weeks. The primary outcome of this study is the intensity of urinary symptoms measured by using International Prostate Symptom Score (IPSS), after the completion of the treatment protocol.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT2013041713043N1**

Registration date: **2013-05-14, 1392/02/24**

Registration timing: **prospective**

Last update:

Update count: **0**

Registration date

2013-05-14, 1392/02/24

Registrant information

Name

Darab Moshtaghi

Name of organization / entity

Bushehr University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 77 1252 0657

Email address

d.moshtaghi@bpums.ac.ir

Recruitment status

Recruitment complete

Funding source

Bushehr University of Medical Sciences

Expected recruitment start date

2013-05-22, 1392/03/01

Expected recruitment end date

2014-05-22, 1393/03/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

The effects of Amitriptylline and Tamsulocin on the urinary symptoms of patients with ureteral stent, a randomized clinical trial.

Public title

The effects of Amitriptylline and Tamsulocin on the urinary symptoms of patients with ureteral stent

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria: The patients who have obstruction of upper urinary tract who are candidate for unilateral ureteral stent
Exclusion criteria: upper urinary tract infection; urogenital system tumor; history of previous urogenital system surgery; neurogenic bladder; bladder stone; overactive bladder; prostatitis; benign prostatic hyperplasia; pregnancy; age more than 60 years and lower than 20 years old

Age

From **20 years** old to **60 years** old

Gender

Both

Phase

3

Groups that have been masked

No information

Sample size

Target sample size: 210

Randomization (investigator's opinion)

Randomized

Randomization description

Blinding (investigator's opinion)

Not blinded

Blinding description

Placebo

Not used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Regional Ethics Committee of Bushehr University of Medical Sciences

Street address

Vice-Chancellor for Research, Bushehr University of Medical Sciences Campus, Salman Farsi St,

City

Bushehr

Postal code

Approval date

2013-04-22, 1392/02/02

Ethics committee reference number

B-92-15-1

Health conditions studied

1

Description of health condition studied

Renal Stone

ICD-10 code

N20.1

ICD-10 code description

Calculus of Ureter

Primary outcomes

1

Description

Urinary Symptoms

Timepoint

A week and three weeks after intervention

Method of measurement

USSQ questionnaire

Secondary outcomes

1

Description

Quality of life

Timepoint

A week and three weeks after intervention

Method of measurement

IPSS questionnaire

2

Description

Bacterial Colonisation

Timepoint

before intervention and 3 weeks later

Method of measurement

culture

Intervention groups

1

Description

Group1: tamsulosin 0.4 mg once daily for 3 weeks as well as ciprofloxacin 500 mg twice a day Group 2: amitriptyline 25 mg once daily for 3 weeks and tamsulosin 0.4 mg once daily for 3 weeks as well as ciprofloxacin 500 mg twice a day Group 3: amitriptyline 25 mg once daily for 3 weeks as well as ciprofloxacin 500 mg twice a day

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Shohadaye Khalij Fars Hospital

Full name of responsible person

Street address

City

Bushehr

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Bushehr University of Medical Sciences

Full name of responsible person

Afshin Ostovar

Street address

Vice-Chancellor for Research, Bushehr University of Medical Sciences Campus, Salman Farsi St,

City

Bushehr

Grant name
Grant code / Reference number
 1500
Is the source of funding the same sponsor organization/entity?
 Yes
Title of funding source
 Bushehr University of Medical Sciences
Proportion provided by this source
 100
Public or private sector
 empty
Domestic or foreign origin
 empty
Category of foreign source of funding
 empty
Country of origin
Type of organization providing the funding
 empty

Person responsible for general inquiries

Contact
Name of organization / entity
 Bushehr University of Medical Sciences
Full name of responsible person
 Darab Moshtaghi
Position
 Urologist / Chancellor of Medical School
Other areas of specialty/work
Street address
 Faculty of Medicine, Bushehr University of Medical Sciences
City
 Bushehr
Postal code
Phone
 +98 77 1252 0657
Fax
Email
 Darabe.20020@yahoo.com
Web page address

Person responsible for scientific inquiries

Contact
Name of organization / entity
 Bushehr University of Medical Sciences
Full name of responsible person
 Darab Moshtaghi

Position
 Urologist / Chancellor of Medical School
Other areas of specialty/work
Street address
 Faculty of Medicine, Bushehr University of Medical Sciences, Moallem st
City
 Bushehr
Postal code
Phone
 +98 77 1252 0657
Fax
Email
 Darabe.20020@yahoo.com
Web page address

Person responsible for updating data

Contact
Name of organization / entity
Full name of responsible person
 Adel Hojabrian
Position
 Medical Student
Other areas of specialty/work
Street address
City
 Bushehr
Postal code
Phone
Fax
Email
 Adel.Hojabrian@yahoo.com
Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)
 empty
Study Protocol
 empty
Statistical Analysis Plan
 empty
Informed Consent Form
 empty
Clinical Study Report
 empty
Analytic Code
 empty
Data Dictionary
 empty